Outbreak of SARS-CoV-2 Delta variant on a single liquified natural gas (LNG) vessel, with estimates of vaccine effectiveness

Authors

  • Nicolas Smoll Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, Australia
  • Jacina Walker Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, Australia
  • Mahmudul Hassan Al Imam Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, Australia
  • Jill Auriac Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, Australia
  • Ross Andrews COVID Incident Management Team, COVID Public Health Response Division, Queensland Health, Australia
  • Andrew Jeremijenko Aspen Medical, 203 Lavarack Avenue, Eagle Farm, Qld 4009, Australia
  • Michael Kirk Central Queensland Hospital and Health Service, Rockhampton, Australia
  • Gulam Khandaker Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, Australia; Central Queensland University, Rockhampton, Australia

DOI:

https://doi.org/10.33321/cdi.2022.46.40

Keywords:

SARS-CoV-2 Delta, COVID-19, outbreak, vaccination, Queensland

Abstract

In August 2021, there was an outbreak of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) Delta variant on an international liquified natural gas (LNG) vessel offshore to Gladstone, Queensland. Fourteen of the 26 crew members aboard the vessel tested positive for SARS-COV-2 on PCR during the outbreak. Vaccine effectiveness (VE) was 52% for all lab-confirmed SARS-CoV-2 infections, 65% for symptomatic SARS-CoV-2 infection and 100% for severe SARS-CoV-2. The attack rate (AR) of SARS-CoV-2 Delta variant was 54% (14/26). With heightened public health measures and infection control practices, we were able to declare the outbreak over in 26 days.

Downloads

Download data is not yet available.

References

Fernandes EG, Santos JDS, Sato HK. Outbreak investigation in cargo ship in times of COVID-19 crisis, Port of Santos, Brazil. Rev Saude Publica. 2020;54:34. doi: https://doi.org/10.11606/s1518-8787.2020054002461.

World Health Organization (WHO). Evaluation of COVID-19 vaccine effectiveness - interim guidance. Geneva: WHO; 17 March 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1.

Torvaldsen S, McIntyre PB. Observational methods in epidemiologic assessment of vaccine effectiveness. Commun Dis Intell Q Rep. 2002;26(3):451–7.

Dhouib W, Maatoug J, Ayouni I, Zammit N, Ghammem R, Ben Fredj S et al. The incubation period during the pandemic of COVID-19: a systematic review and meta-analysis. Syst Rev. 2021;10(1):101. doi: https://doi.org/10.1186/s13643-021-01648-y.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(25):2603–15. doi: https://doi.org/10.1056/NEJMoa2034577.

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97. doi: https://doi.org/10.1016/S0140-6736(20)31866-3.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi: https://doi.org/10.1016/S0140-6736(20)32661-1.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi: https://doi.org/10.1056/NEJMoa2035389.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201. doi: https://doi.org/10.1056/NEJMoa2101544.

Kordsmeyer AC, Mojtahedzadeh N, Heidrich J, Militzer K, von Münster T, Belz L et al. Systematic review on outbreaks of SARS-CoV-2 on cruise, navy and cargo ships. Int J Environ Res Public Health. 2021;18(10):5195. doi: https://doi.org/10.3390/ijerph18105195.

Codreanu TA, Ngeh S, Trewin A, Armstrong PK. Successful control of an onboard COVID-19 outbreak using the cruise ship as a quarantine facility, Western Australia, Australia. Emerg Infect Dis. 2021;27(5):1279–87. doi: https://doi.org/10.3201/eid2705.204142.

Tokuda Y, Sakihama T, Aoki M, Taniguchi K, Deshpande GA, Suzuki S et al. COVID-19 outbreak on the Diamond Princess cruise ship in February 2020. J Gen Fam Med. 2020;21(4):95–7. doi: https://doi.org/10.1002/jgf2.326.

Kasper MR, Geibe JR, Sears CL, Riegodedios AJ, Luse T, Von Thun AM et al. An outbreak of Covid-19 on an aircraft carrier. N Engl J Med. 2020;383(25):2417–26. doi: https://doi.org/10.1056/NEJMoa2019375.

Lee BU. A high attack rate of 90% of SARS-CoV-2 Delta variant infections in crew personnel on a single navy ship. J Travel Med. 2021:taab168. doi: https://doi.org/10.1093/jtm/taab168.

Downloads

Published

18/08/22

How to Cite

Smoll, Nicolas, Jacina Walker, Mahmudul Hassan Al Imam, Jill Auriac, Ross Andrews, Andrew Jeremijenko, Michael Kirk, and Gulam Khandaker. 2022. “Outbreak of SARS-CoV-2 Delta Variant on a Single Liquified Natural Gas (LNG) Vessel, With Estimates of Vaccine Effectiveness”. Communicable Diseases Intelligence 46 (August). https://doi.org/10.33321/cdi.2022.46.40.

Issue

Vol. 46 (2022)

Section

Short report

Categories

License

Copyright (c) 2022 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 > >>